Objective:To investigate the practical value of pancreatic duct bind with supporting tube combined with single-needle suture for pancreaticojejunostomy in laparoscopic pancreaticoduodenectomy (LPD).Methods:The clinical data of 65 patients with pancreatic head or periampullary tumors who underwent LPD at the First Affiliated Hospital of Kunming Medical University between January 2021 and June 2024 were retrospectively analysed. Among them, 31 were male and 34 were female, aged (57.7±13.3) years. The patients were divided into two groups based on the method of pancreaticojejunostomy: 22 patients who underwent pancreatic duct bind with supporting tube single-needle suture pancreaticojejunos-tomy were included in the study group, 43 patients who underwent traditional pancreatic duct-to-mucosa pancreaticojejunostomy were included in the control group. The clinical data of the patients, including gender, age, operation time, pancreaticojejunostomy time, and postoperative complications, etc. were recorded.Results:Compared with the control group, the pancreaticojejunostomy time [(25.3±2.4) min vs. (47.0±3.9) min] and operation time [(425.2±52.1) min vs. (453.7±30.8) min] of the study group were both shortened, and the differences were statistically significant (both P<0.05). There was no statistically significant difference in the postoperative complication rate between the study group and the control group [18.2% (4/22) vs. 34.9% (15/43), P=0.161]. The incidence of clinically relevant pancreatic fistula in the study group was lower than that in the control group [4.5% (1/22) vs. 30.2% (13/43)], and the difference was statistically significant ( P=0.024). Conclusion:Pancreatic duct bind with supporting tube combined with single-needle suture pancreaticojejunostomy is safe and effective in LPD. Compared with traditional pancreatic duct-to-mucosa pancreaticojejunostomy, pancreatic duct bind with supporting tube combined with single-needle suture pancreaticojejunostomy has advantages in terms of clinically relevant pancreatic fistula rate, operation time, and pancreaticojejunostomy time.

Objective To explore the molecular mechanism of circFARSA targeting miR-4319 to modulate the prolifera-tive,migratory and invasive abilities of Huh-7 liver cancer cells.Methods The qRT-PCR method was used to detect the expres-sion of circFARSA and miR-4319 in liver cancer tissues and adjacent tissues.Liver cancer cells Huh-7 were cultured in vitro,qRT-PCR method was used to detect the expression of circFARSA and miR-4319 in Huh-7 cells.CCK-8 assay and Transwell chamber assay were used to detect proliferation,migration,and invasion abilities,respectively.Dual-luciferase reporter assay was performed to analyze the interaction between circFARSA and miR-4319.Western blot was used to detect Ki-67,MMP-2 and MM P-9 protein levels.Results The level of circFARSA was increased,and the level of miR-4319 was decreased in liver cancer tissues(bothP＜0.05).Cell viability,migration,and invasion were significantly inhibited after circFARSA silencing or miR-4319 overexpression(all P＜0.05).It was verified by double luciferase reporter gene experiment that circFARSA could competi-tively bind to miR-4319.Co-transfection of circFARSA siRNA with miR-4319 inhibitor enhanced cell viability,migration,and invasion when compared with transfection of circFARSA siRNA alone(P＜0.05).Conclusion circFARSA knockdown sup-pressed liver cancer cell tumor property by increasing the expression level of miR-4319.

Single-incision laparoscopic cholecystectomy (SILC) represents a significant evolution in minimally invasive surgery, designed to accomplish cholecystectomy via a single umbilical incision. This approach seeks to reduce abdominal wall trauma while optimizing cosmetic outcomes. SILC is a safe and feasible minimally invasive technique for cholecystectomy under defined conditions; however, its broader adoption will require further evidence-based research and the establishment of standardized protocols to support its widespread implementation. When performed by skilled surgeons in carefully selected patients, SILC demonstrates clinical outcomes comparable to those of conventional multiport laparoscopic cholecystectomy, with notable improvements in incision aesthetics. Nonetheless, the technique is limited by a constrained operative field and a protracted learning curve. In response, continuous advancements in instrumentation and procedural modifications have propelled the further development and clinical integration of SILC. Drawing on current literature and clinical experience, this review delineates the technical characteristics, current clinical applications, primary benefits, and prevailing challenges associated with SILC.

Objective To explore the molecular mechanism of circFARSA targeting miR-4319 to modulate the prolifera-tive,migratory and invasive abilities of Huh-7 liver cancer cells.Methods The qRT-PCR method was used to detect the expres-sion of circFARSA and miR-4319 in liver cancer tissues and adjacent tissues.Liver cancer cells Huh-7 were cultured in vitro,qRT-PCR method was used to detect the expression of circFARSA and miR-4319 in Huh-7 cells.CCK-8 assay and Transwell chamber assay were used to detect proliferation,migration,and invasion abilities,respectively.Dual-luciferase reporter assay was performed to analyze the interaction between circFARSA and miR-4319.Western blot was used to detect Ki-67,MMP-2 and MM P-9 protein levels.Results The level of circFARSA was increased,and the level of miR-4319 was decreased in liver cancer tissues(bothP＜0.05).Cell viability,migration,and invasion were significantly inhibited after circFARSA silencing or miR-4319 overexpression(all P＜0.05).It was verified by double luciferase reporter gene experiment that circFARSA could competi-tively bind to miR-4319.Co-transfection of circFARSA siRNA with miR-4319 inhibitor enhanced cell viability,migration,and invasion when compared with transfection of circFARSA siRNA alone(P＜0.05).Conclusion circFARSA knockdown sup-pressed liver cancer cell tumor property by increasing the expression level of miR-4319.

Objective:To investigate the practical value of pancreatic duct bind with supporting tube combined with single-needle suture for pancreaticojejunostomy in laparoscopic pancreaticoduodenectomy (LPD).Methods:The clinical data of 65 patients with pancreatic head or periampullary tumors who underwent LPD at the First Affiliated Hospital of Kunming Medical University between January 2021 and June 2024 were retrospectively analysed. Among them, 31 were male and 34 were female, aged (57.7±13.3) years. The patients were divided into two groups based on the method of pancreaticojejunostomy: 22 patients who underwent pancreatic duct bind with supporting tube single-needle suture pancreaticojejunos-tomy were included in the study group, 43 patients who underwent traditional pancreatic duct-to-mucosa pancreaticojejunostomy were included in the control group. The clinical data of the patients, including gender, age, operation time, pancreaticojejunostomy time, and postoperative complications, etc. were recorded.Results:Compared with the control group, the pancreaticojejunostomy time [(25.3±2.4) min vs. (47.0±3.9) min] and operation time [(425.2±52.1) min vs. (453.7±30.8) min] of the study group were both shortened, and the differences were statistically significant (both P<0.05). There was no statistically significant difference in the postoperative complication rate between the study group and the control group [18.2% (4/22) vs. 34.9% (15/43), P=0.161]. The incidence of clinically relevant pancreatic fistula in the study group was lower than that in the control group [4.5% (1/22) vs. 30.2% (13/43)], and the difference was statistically significant ( P=0.024). Conclusion:Pancreatic duct bind with supporting tube combined with single-needle suture pancreaticojejunostomy is safe and effective in LPD. Compared with traditional pancreatic duct-to-mucosa pancreaticojejunostomy, pancreatic duct bind with supporting tube combined with single-needle suture pancreaticojejunostomy has advantages in terms of clinically relevant pancreatic fistula rate, operation time, and pancreaticojejunostomy time.

For Perihilar cholangiocarcinoma (pCCA), surgical resection is the only effective way to cure this disease. However, it has high postoperative mortality and high recurrence rate. Domestic and foreign scholars have constructed statistics-based evaluation methods to predict patients′ postoperative survival and complications, such as nomogram, scoring system and other prognostic models. Based on these methods, clinicians can better select patients who can benefit from surgery and choose the optimal? treatment for more severe patients. Through the adoption of other treatments or some ways to ameliorate some preoperative condition, to improve the patient′s mortality and survival. This article reviews the prognostic risk factors and prognostic models of pCCA in order to provide a reference for clinicians to predict the prognosis about the surgery.

Objective To reveal the correlation between follistatin-like protein 1(FSTL1)level and severity of ventricular arrhythmia.Methods A total of 107 patients treated in our department from October 2019 to September 2020 were recruited and divided into control group(40 cases),accidental premature ventricular contraction(PVC)group(35 cases),frequent PVC group(20 cases)and ventricular tachycardia(VT)group(12 cases)according to the Lown's grading.The blood content of FSTL1 was determined by ELISA,and its expression level was detected by RT-qPCR.Electrocardiographic indicators,blood FSTL1 content and relative level of FSTL1 were compared among the four groups.Results The FSTL1 content was significantly higher in the fre-quent PVC group and the VT group than the control group[(39.62±14.29)ng/L and(50.66±21.37)ng/L vs(24.58±10.15)ng/L,P＜0.05],so was the content in the frequent PVC group and the VT group than the accidental PVC group[(39.62±14.29)ng/L and(50.66±21.37)ng/L vs(31.83±9.54)ng/L,P＜0.05].The VT group had significantly higher FSTL1 than the frequent PVC group[(50.66±21.37)ng/L vs(39.62±14.29)ng/L,P＜0.05].The mRNA level of FSTL1 was significantly higher in the frequent PVC group and the VT group than the control group and the accidental PVC group(P＜0.05),and in the VT group than the frequent PVC group(P＜0.05).Conclusion To a certain extent,the blood FSTL1 content is positively correlated with the severity of ventricular arrhythmia,which may be a new target for disease warming.

Objective To reveal the correlation between follistatin-like protein 1(FSTL1)level and severity of ventricular arrhythmia.Methods A total of 107 patients treated in our department from October 2019 to September 2020 were recruited and divided into control group(40 cases),accidental premature ventricular contraction(PVC)group(35 cases),frequent PVC group(20 cases)and ventricular tachycardia(VT)group(12 cases)according to the Lown's grading.The blood content of FSTL1 was determined by ELISA,and its expression level was detected by RT-qPCR.Electrocardiographic indicators,blood FSTL1 content and relative level of FSTL1 were compared among the four groups.Results The FSTL1 content was significantly higher in the fre-quent PVC group and the VT group than the control group[(39.62±14.29)ng/L and(50.66±21.37)ng/L vs(24.58±10.15)ng/L,P＜0.05],so was the content in the frequent PVC group and the VT group than the accidental PVC group[(39.62±14.29)ng/L and(50.66±21.37)ng/L vs(31.83±9.54)ng/L,P＜0.05].The VT group had significantly higher FSTL1 than the frequent PVC group[(50.66±21.37)ng/L vs(39.62±14.29)ng/L,P＜0.05].The mRNA level of FSTL1 was significantly higher in the frequent PVC group and the VT group than the control group and the accidental PVC group(P＜0.05),and in the VT group than the frequent PVC group(P＜0.05).Conclusion To a certain extent,the blood FSTL1 content is positively correlated with the severity of ventricular arrhythmia,which may be a new target for disease warming.

Cholangiocarcinoma is a group of highly invasive and heterogeneous biliary malignancies originating from any part of the biliary tree. At present, the most ideal treatment is still radical surgery.Gemcitabine combined with cisplatin (gem-cis) has been recognized as the standard first-line chemotherapy regimen for patients with unresectable, advanced or metastatic disease.In recent years, with the proposal of precision medicine and the development of next-generation sequencing technologies, A large number of important cholangiocarcinoma targets have been discovered, such as FGFR, IDH, VEGFR, BRAF, MET, etc., and the research on corresponding target drugs is booming.By referring to relevant literature and data, combined with domestic and foreign clinical trials, this paper reviews the important targets of cholangiocarcinoma and the latest progress of targeted drug therapy.

Liver is the most important metastatic target organ of colorectal cancer. Nearly 50% of colorectal patients are found to have liver metastasis during the course of the disease, including 25% of colorectal patients undergoing simultaneous liver metastasis and the other 25% undergoing metachronous liver metastasis. Liver metastasis is the main cause of death for colorectal patients and the prevention and treatment of colorectal cancer liver metastasis is the top priority to overcome the disease. Active surgical treatment can bring survival benefits to colorectal patients. The authors analyze and summarize the multidisciplinary treatment of colorectal liver metastasis in the department of organ transplantation of First Affiliated Hospital of Kunming Medical University to discuss the hepatectomy strategy of colorectal liver metastasis.